Skip to main content


[18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy

Article metrics



To compare the prognostic value of different anatomical and functional metabolic parameters determined using [18F]FDG-PET/CT with other clinical and pathological prognostic parameters in cervical cancer (CC).


Thirty-eight patients treated with standard curative doses of chemo-radiotherapy (CRT) underwent pre- and post-therapy [18F]FDG-PET/CT. [18F]FDG-PET/CT parameters including mean tumor standardized uptake values (SUV), metabolic tumor volume (MTV) and tumor glycolytic volume (TGV) were measured before the start of CRT. The post-treatment tumor metabolic response was evaluated. These parameters were compared to other clinical prognostic factors. Survival curves were estimated by using the Kaplan-Meier method. Cox regression analysis was performed to determine the independent contribution of each prognostic factor.


After 37 months of median follow-up (range, 12–106), overall survival (OS) was 71 % [95 % confidence interval (CI), 54–88], disease-free survival (DFS) 61 % [95 % CI, 44–78] and loco-regional control (LRC) 76 % [95 % CI, 62–90]. In univariate analyses the [18F]FDG-PET/CT parameters unfavorably influencing OS, DFS and LRC were pre-treatment TGV-cutoff ≥562 (37 vs. 76 %, p = 0.01; 33 vs. 70 %, p = 0.002; and 55 vs. 83 %, p = 0.005, respectively), mean pre-treatment tumor SUV cutoff ≥5 (57 vs. 86 %, p = 0.03; 36 vs. 88 %, p = 0.004; 65 vs. 88 %, p = 0.04, respectively) and a partial tumor metabolic response after treatment (9 vs. 29 %, p = 0.0008; 0 vs. 83 %, p < 0.0001; 22 vs. 96 %, p < 0.0001, respectively). After multivariate analyses a partial tumor metabolic response after treatment remained as an independent prognostic factor unfavorably influencing DFS and LRC (RR 1:7.7, p < 0.0001, and RR 1:22.6, p = 0.0003, respectively) while the pre-treatment TGV-cutoff ≥562 negatively influenced OS and DFS (RR 1:2, p = 0.03, and RR 1:2.75, p = 0.05).


Parameters capturing the pre-treatment glycolytic volume and metabolic activity of [18F]FDG–positive disease provide important prognostic information in patients with CC treated with CRT. The post-therapy [18F]FDG-PET/CT uptake (partial tumor metabolic response) is predictive of disease outcome.


Cervical cancer (CC) is the second most common cancer among women in the world and a leading cause of cancer mortality [1]. Since the publication in 1999 of randomized trials using platinum-based chemotherapy (PBCT) in patients with locally-advanced cervical cancer (LACC) and the clinical recommendations announced by the National Cancer Institute, concurrent radiotherapy (RT) and cisplatin-based chemotherapy became the standard management with a significant improvement in survival rates compared with RT alone [26]. More recently other trials suggested that there might be a benefit for sequential chemotherapy after standard concomitant chemo-radiotherapy (CRT) and this therapeutic approach is now being tested in randomized trials [7, 8]. The gains in survival observed with CRT have come at a substantial price because both acute and late morbidities increased with combined modality treatment. It is thus expected that intensifying the PBCT regimen would increase side effects and reduce the patient’s quality of life. Even with the significant reductions in the risk of CC death observed with CRT, the absolute gains are small for patients with early tumors, many of whom could have been cured with RT alone and recurrence rates are still high for patients with very large or advanced tumors for whom adjuvant chemotherapy might be of benefit [7]. It is therefore important to establish accurate predictors of CRT response, particularly if adjuvant chemotherapy after primary CRT should become the new treatment paradigm.

Some clinical and pathological prognostic factors including age, histological tumor type, tumor grade, large tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage, pelvic and para-aortic lymph node metastasis, lympho-vascular space invasion (LVSI) and anemia are currently considered important for survival and/or treatment outcome [911]. By using these prognostic factors and despite carefully implemented treatment it is estimated that 30-40 % of patients with LACC will still recur and eventually die from the disease. Therefore additional research efforts have concentrated on prognostic factors to accurately predict the prognoses of patients with LACC [12]. Advances in the understanding of the tumor microenvironment such as hypoxia [11, 13, 14], interstitial fluid pressure [15, 16], angiogenesis [17, 18] and the immune landscape [19, 20] open the window to implement new therapeutic approaches and to tailor intensified treatment to those patients considered as having a significant risk of recurrence or death. There is a high level of evidence that 18F-labeled fluorodeoxyglucose positron emission tomography [18F]FDG-PET/CT plays an essential role in the primary evaluation of CC, particularly in evaluating lymph nodal status and distant metastases, contributing to precise tumor staging and changes in therapeutic attitudes [21]. [18F]FDG-PET/CT is also important as a predictor of treatment outcome after CRT [22]. The maximum standardized uptake value (SUVmax) of the primary tumor, a semi-quantitative parameter derived from [18F]FDG-PET/CT, is known to be a significant prognostic factor in many types of cancers as well as CC [2325]. However, this parameter is a single voxel value and does not reflect the metabolism of the whole tumor. Other volumetric [18F]FDG-PET/CT parameters such as average SUV (SUVmean), metabolic tumor volume (MTV) and total glycolytic activity within the tumor volume (TGV) are easily acquired using a threshold-based automatic volume of interest technique [26].

In this study we compared the prognostic values of various volume-based metabolic parameters including SUVmax, SUVmean, MTV, and TGV determined using [18F]FDG-PET/CT with other clinical and pathological prognostic parameters in patients with LACC treated with CRT. The purpose of this study was to establish whether tumor SUV, MTV and TGV add prognostic information to clinical prognostic factors in patients with LACC.


After approval by the local ethics committee, we retrospectively reviewed the charts of 38 consecutive eligible patients who presented an intact LACC and were treated with concomitant cisplatin and RT between 2007 and 2014. Inclusion criteria were pathological diagnosis of CC, stage IB1-IVA according to the FIGO 2009 definition. Patients with stage IB1 and IIA1 were considered for inclusion if they had positive lymph nodes. Patients were also required to have staging by examination under anesthesia, [18F]FDG-PET/CT imaging and pelvic magnetic resonance imaging (MRI) at diagnosis, a minimum 6-month follow-up and a second [18F]FDG-PET/CT image three months after completing CRT. Exclusion criteria were history of previous chemotherapy or RT and metastatic disease. Patients with positive pelvic/para-aortic lymph nodes were not considered as FIGO IVB (metastatic) because these patients can still undergo a curative cisplatin-based CRT treatment. We thus included patients with positive nodes in our analysis.

Data were obtained from the electronic and written medical records and included age at diagnosis, date of diagnosis, histology, grade, presence of LVSI, FIGO stage, presence of positive lymph nodes confirmed by [18F]FDG-PET/CT, tumor size measured on MRI, tumor SUVmean, tumor SUVmax, MTV, TGV, body mass index, complete blood counts (CBC) before treatment (white blood cells, platelets, hemoglobin), RT dose (including brachytherapy dose), metabolic tumor response measured by [18F]FDG-PET/CT at three months post-treatment, SUVmax, SUVmean, TGV and MTV of tumors at recurrence, date and location of recurrence, date of last follow-up and date of death.

Recurrences were grouped into local (vaginal and/or cervical recurrences), regional (pelvic/para-aortic recurrences), and distant (upper abdominal and/or extra-abdominal).

[18F]FDG-PET/CT acquisition parameters

All patients fasted for at least 6 h before the PET study. The [18F]FDG-PET/CT was performed 60 min after administration of 3.5 MBq/kg [18F]]FDG (Discovery 690FX TOF; GE Healthcare, Milwaukee, WI) and images (from the head to proximal thigh) were reconstructed using time-of-flight and point-spread function information. The SUV was calculated by correcting for the injected dose of [18F]-FDG and patient’s body weight. An increase in FDG uptake above a SUV of 2.5 g/ml was used to define malignancy based on previous publications [2729].

[18F]FDG-PET-CT tumor measurements

All PET/CT studies were retrieved from the electronic archival system and were then reviewed on a workstation (Velocity Advanced Image Software; Velocity Medical Solutions, Atlanta, GA), PET, CT, and deformable registered PET/CT images were reviewed in axial, coronal and sagittal planes. For the purposes of this study the relevant imaging biomarker measurements were tumor SUVmax, SUVmean, MTV and TGV obtained from the pre-treatment PET. The SUVmax was defined as the maximum SUV within the tumor. SUVmean was calculated by computing the average SUV within a region of interest (tumor). The MTV was defined as the FDG avid tumor volume measured bi-dimensionally at the longest diameter. The total glycolytic activity within the tumor volume or TGV was defined as follows:

$$ \mathrm{M}\mathrm{T}\mathrm{V}\kern0.5em \times \kern0.5em \mathrm{SUVmean}, $$

where MTV is the metabolic tumor volume and SUVmean is the mean SUV. Once the primary tumor was auto-segmented, the software automatically calculated the SUVmax, SUVmean, MTV, and TGV [26].

Metabolic tumor volume defines the volume of the tumor on the basis of the distribution of metabolic activity instead of the traditional CT densities that depend on electron density of the target. TGV goes a step further and effectively weighs this volume by its mean metabolic activity. Hence, a large TGV may reflect a small volume with high metabolic activity (high SUVmean) or a large volume with a lower metabolic activity. These two conditions are different and may be related to different tumor blood supply, microenvironment conditions, tumor hypoxia, etc. [30]. To better assess the outcome of these patients, taking into account these two different conditions, we dichotomized the MTV and the SUVmean at the sample median. This dichotomization allowed us to group patients below or above the variable in question (group A: patients with MTV below the median, group B: patients with MTV above the median, group C: patients with SUV below the median, group D: patients with SUV above the median). Based on the MTV and SUV dichotomization, patients were then stratified in four different categories:

  • Group A + C: Patients with MTV below the median + patients with mean SUV below the median

  • Group A + D: Patients with MTV below the median + patients with mean SUV above the median

  • Group B + C: Patients with MTV above the median + patients with mean SUV below the median

  • Group B + D: Patients with MTV above the median + patients with mean SUV above the median

Post-treatment metabolic response was determined qualitatively using the following definitions: complete metabolic response (CMR) was defined as absence of abnormal FDG uptake at sites of abnormal FDG uptake noted on the pre-treatment [18F]FDG-PET/CT study. Partial metabolic response (PMR) was defined as any persistent abnormal FDG uptake at these sites. Progressive disease (PD) was defined as any new sites of abnormal FDG uptake that were not present on the pre-treatment PET [22].

We also obtained the SUVmax, SUVmean, MTV, and TGV from the [18F]FDG-PET/CT from patients that had partial metabolic response after chemo-radiotherapy treatment.

Cisplatin and radiotherapy administration

Chemotherapy consisted of weekly cisplatin (40 mg/m2) delivered concurrently with RT. Neither induction nor adjuvant chemotherapy was administered.

Before starting RT treatment, patients underwent a pelvic computed tomography (CT) scan (planning scan) with intravenous contrast medium. They were scanned in a supine position with a head and knee support. For the CT-planning scan, standard acquisition parameters were used (tension, 120 kV; tube rotation time 1 s; tube current, 160 mA; helical acquisition with pitch of 0.938; reconstructed image thickness, 2 mm). Consortium guidelines were used to contour the pelvic clinical target volume (CTV) [31]. According to the same guidelines, a 1.5-cm uniform margin was added around the CTV to obtain the pelvic planning target volume (PTV). The nodal CTV was delineated according to the published guidelines, with a 7-mm uniform margin to obtain the nodal PTV [32]. The small bowel, sigmoid, rectum, bladder and femoral heads were contoured as organs at risk. Treatment plans were performed using the Tomotherapy treatment planning system (Accuray Inc, Sunnyvale, CA) with a field width of 5 cm and a pitch of 0.287. Pelvic radiation dose was 45–50.4 Gy in 1.8-Gy daily fractions, in 25–28 fractions. In patients with positive pelvic or para-aortic nodes, extended field RT was used to a dose of 45 Gy with a simultaneous integrated boost to the positive nodes of 60 Gy in 2.4-Gy per fraction in 25 fractions. Daily image guidance before each fraction was implemented using the MV fan-beam CT of Tomotherapy. Patients received 3–4 fractions of MRI-guided high-dose-rate (HDR) intracavitary brachytherapy every 4 days. The prescribed dose was 7 Gy to the high-risk CTV. Brachytherapy was administered after the end of external beam RT.

Clinical and imaging follow-ups

Clinical follow-up exams of the patients were performed weekly during CRT and after the completion of therapy as follows: every 3 months until 24 months, every 6 months during years 2–5, and annually thereafter. All the patients in this series had a [18F]FDG-PET/CT evaluation at three months following CRT to assess tumor response. Subsequently follow-up imaging studies consisted of MRI/CT and/or [18F]FDG-PET/CT if clinically indicated. Recurrences were biopsy/surgical specimen proven in more than 50 % of the cases of recurrent disease and in the remainder of the cases recurrences were proved by [18F]FDG-PET/CT.

Statistical considerations

Survival curves were computed using the Kaplan-Meier method [33]. Time to any event was measured from the day of diagnosis. Death certificates confirmed date of deaths. If clinical or pathological evidence of active, recurrent disease was present, deaths were attributed to CC. The events were death (all causes) for overall survival (OS) and death (all causes) or relapse for disease-free survival (DFS). For the loco-regional control (LRC) rate the event consisted of local or regional relapse.

Confidence intervals (CI) were calculated from standard errors. In univariate analyses differences between groups were assessed using the log-rank test.

All variables were dichotomized using cutoffs reported in the literature when available or the best discriminating value as determined by recursive partitioning [34].

In multivariate analyses we screened for prognostic factors with a p-value of less than 0.05 in univariate analyses by using the Cox regression analysis to define the independent contribution of each prognostic factor [35].

Unpaired Student’s t test was used to compare means of two individual groups.

A p value of  0.05 was considered to be statistically significant. All data were examined using JMP version 10.0.0 (SAS Institute Inc., Cary, NC).


Patient and tumor characteristics

A total of 38 patients with LACC were identified who fulfill the inclusion criteria. Patients’ surgical, pathological and treatment characteristics are detailed in Table 1. The median age was 52.5 years (range, 26–83 years). The median tumor size was 4.5 cm (range, 2–8 cm). The median body-mass index at diagnosis was 23 (range, 14–42). The median CBC at baseline was 8.55 · 103/mL (range, 4.6–25.6) for white blood cells; 130 g/dL (range, 71–149) for hemoglobin; 273.5 · 103/mL (range, 186–819) for platelets.

Table 1 Patient and tumor characteristics in 38 patients treated with cervical cancer treated with chemo-radiotherapy

The pre-treatment tumors’ average SUVmax, SUVmean, MTV, and TGV (range) were 17.8 g/mL (4.3–34.6), 4.24 g/mL (2–8.28), 114.16 cm3 (19.73–546.12), and 493.75 (55.83–2991); respectively.

In patients with PMR, the three-months post-treatment primary tumor’s average SUVmax, SUVmean, MTV, and TGV (range) were 18.4 g/mL (4–20), 10.38 g/mL (3.5–17), 43.15 cm3 (6–35.4), 521.64 (72–2496); respectively.

Cisplatin and radiotherapy treatment

All patients received, as planned, 5 cycles of cisplatin combined with RT. Four patients had cisplatin dose modifications: 2 because of renal toxicity and 2 because of leucopenia. In these 4 patients the cisplatin dose was reduced to 30 mg/m2 and 20 mg/m2 respectively. The median pelvic radiation dose was 45 Gy (range, 45–50.4 Gy). Twenty-two patients received extended-field RT to the para-aortic lymph nodes. All women received HDR brachytherapy with a median dose of 28 Gy (range, 21–28 Gy) in 3–4 fractions. No patient experienced delays or breaks in RT because of short-term toxicity (median RT duration, 41 days; range, 32–51 days).

Disease outcome

After a median follow-up period of 37 months (range, 6–106 months), the 3-year OS was 71 % (95 % CI, 54–88), DFS 61 % (95 % CI, 44–78) and LRC 76 % (95 % CI, 62–90). By the end of follow-up 24 out of 38 (63.15 %) patients were alive and without disease. A total of 14 patients (36.84 %) experienced a recurrence. Nine patients had a local recurrence, 3 of them presented also with regional nodal recurrence and five patients had distant metastases. All the patients with recurrence died of CC. The nine patients with local recurrence had a PMR three months post-primary CRT treatment. For these patients the [18F]FDG-PET/CT allowed the detection of “in field” local/regional recurrence which were biopsy proven. Five of these patients were offered salvaged surgery, and had a median time since the diagnosis of recurrence to death of 10.5 months being systemic disease the main cause of death. The remaining 4 patients with local PMR presented also systemic disease at the post-treatment [18F]FDG-PET/CT and the median time since the diagnosis of recurrence to death was 6 months.

For the nine patients with PMR three months after CRT, the mean (±SD) pre-post-therapy TGV were 957 (±1049) and 521 (±773), respectively (unpaired student t test, p = 0.33), and the mean (±SD) pre-post-therapy MTV were 126 (±109) and 43 (±46), respectively (unpaired student t test, p = 0.05).

In univariate analyses (Table 2) the [18F]FDG-PET/CT parameters unfavorably influencing OS, DFS and LRC were pre-treatment TGV-cutoff ≥562 (37 vs. 76 %, p = 0.01; 33 vs. 70 %, p = 0.002; and 55 vs. 83 %, p = 0.005, respectively), pre-treatment tumor SUVmean-cutoff ≥5 (57 vs. 86 %, p = 0.03; 36 vs. 88 %, p = 0.004; 65 vs. 88 %, p = 0.04, respectively), and a partial tumor metabolic response after treatment (9 vs. 29 %, p = 0.0008; 0 vs. 83 %, p < 0.0001; 22 vs. 96 %, p < 0.0001, respectively). (Figures 1, 2 and 3). After subgroup analysis based on the MTV and SUV dichotomization, patient’s in-group A + C and B + C had significantly better OS, DFS, and LRC than patient’s in-group A + D and B + D (Table 2 and Fig. 4).

Table 2 Univariate analysis in 38 patients treated with cervical cancer treated with chemo-radiotherapy
Fig. 1

Univariate analysis. [18F]FDG-PET/CT Standard uptake value (SUV) mean cutoff ≥5 (blue curve) before starting chemo-radiotherapy unfavorably influenced: a) Overall survival (86 vs. 57 %, p = 0.03), b) Disease-free survival (88 vs. 36 %, p = 0.004), and c) Locoregional control (88 vs. 65 %, p = 0.04)

Fig. 2

Univariate analysis. [18F]FDG-PET/CT tumor glycolytic volume (cutoff ≥562) before starting chemo-radiotherapy unfavorably (blue curve) influenced: a) Overall survival (37 vs. 76 %, p = 0.01), b) Disease-free survival (33 vs. 70 %, p = 0.002), and c) Locoregional control (55 vs. 83 %, p = 0.04)

Fig. 3

Univariate analysis. [18F]FDG-PET/CT partial tumor metabolic response after treatment unfavorable (blue curve) influenced: a) Overall survival (9 vs. 29 %, p = 0.0008); b) Disease-free survival (0 vs. 83 %, p < 0.0001); and c) Locoregional control (22 vs. 96 %, p < 0.0001)

Fig. 4

Univariate analysis. Subgroup analysis based on the dichotomization of MTV and SUVmean at the sample median. In green group B + C: Patients with MTV above the median + patients with mean SUV below the median. In red group A + C: Patients with MTV below the median + patients with mean SUV below the median. In orange group A + D: Patients with MTV below the median + patients with mean SUV above the median. In blue group B + D: Patients with MTV above the median + patients with mean SUV above the median. a) Overall survival: B + C 87 %, A + C 83 %, A + D 68 %, B + D 0 %; p < 0.003. b) Disease-free survival: B + C 90 %, A + C 83 %, A + D 50 %, B + D 25 %; p < 0.0003. c) Locoregional control: B + C 90 %, A + C 83 %, A + D 78 %, B + D 50 %; p < 0.03

Patients with squamous-cell carcinoma had a statistically significant better clinical outcome than patients with adenocarcinomas (OS: 75 vs. 50 %, p = 0.02, DFS 65 vs. 26 %, p = 0.02).

After multivariate analyses a partial tumor metabolic response after treatment remained as an independent prognostic factor unfavorably influencing DFS and LRC (RR 1:7.7, p < 0.0001, and RR 1:22.6, p = 0.0003, respectively) while the pre-treatment TGV-cutoff ≥562 negatively influenced OS and DFS (RR 1:2, p = 0.03, and RR 1:2.75, p = 0.05) (Table 3).

Table 3 Cox multivariate analysis in 38 patients with cervical cancer treated with chemo-radiotherapy


We investigated the prognostic values of [18F]FDG-PET/CT volume-based metabolic parameters and we compared them with other clinical and pathological prognostic factors in LACC patients undergoing CRT. Our study shows that the pre-treatment TGV, the pre-treatment tumor SUVmean, and the metabolic response are important independent prognostic factors for survival and recurrence. There is an increasing interest in the utilization of functional parameters in tumor-volume delineation because metabolic data may significantly improve the determination of the biologically relevant volume and the heterogeneity within the tumor. In our series TGV remained statistically significant as a predictor of DFS in the multivariate analysis. It is thus important to differentiate the TGV from other metabolic parameters evaluated in our study (pre-treatment SUVmax, SUVmean and MTV). While standardized uptake value can only represent metabolic activity as a semiquantitative index for tumor uptake, MTV represents the number of active metabolic tumor cells and the combination of both (TGV) is a more effective prognostic factor that takes into account both metabolic activity and tumor volume as important parameters of tumor response to therapy. Our results suggest also that the combination of uptake intensity (SUVmean) and MTV analysis improved the identification of poor prognosis subtype. It is possible that at a local level, these tumor differences of intensity between contiguous voxels represent heterogeneity parameters associated with tumor regions of increased or reduced metabolism determined by different microenvironmental conditions.

The TGV has also been associated with therapeutic response and survival in other tumors [3638]. The TGV cutoff reported in our series probably reflects the increased recurrence and mortality in patients with large growing tumor burden (metabolically active fraction). For these patients it is probable that the volume of the tumor at presentation determines the mortality within one or two years, linking tumor aggressiveness with disease burden. These patients could be those that benefit from adjuvant intensified PBCT regimens.

Other functional measurements like SUVmean and SUVmax have been reported as prognostic in CC outcome in a number of studies. Kidd et al. showed that the SUVmax of the tumor is a sensitive biomarker for prognosis in patients with uterine CC [23]. In a study where repetitive PET/CT images of CC patients were taken during CRT, the SUVmax shows a consistent rate of decline during treatment and declines at a faster rate than MTV regresses, representing also an earlier tool for prediction of tumor response [39].

One third of patients with LACC will have disease recurrence, usually within 2 years of completing treatment. The most important predictors of disease recurrence include clinical stage, lymph node status at diagnosis, tumor histology and early tumor response after treatment [12, 22]. After CRT as definitive treatment of LACC there is sufficient evidence to support the use of [18F]FDG-PET/CT for the assessment of treatment response. The presence of FDG activity (either persistent or new) can predict survival outcome. In accordance with our series, a study in which [18F]FDG-PET/CT was performed 3 months after completion of treatment showed that a metabolic response was predictive of long-term survival, with a 3-year survival rate of 78 % in patients with a CMR, 33 % in patients with a PMR and 0 % in those with PD. Multivariate analysis in that study showed that post-treatment response and lymph node status at diagnosis were the only accurate predictors of DFS [22]. Standard surveillance programs have proposed the use of routine physical examinations and patient’s symptoms education to facilitate early disease recurrence. However, by fully exploiting the diagnostic information derived from pre- and post-treatment [18F]FDG-PET/CT, patients with adverse metabolic prognostic factors could potentially benefit from either adjuvant systemic therapy or salvage curative therapy in the case of disease recurrence [40, 41]. In our study we observed that in patients with local PMR three-months post CRT, the difference in pre-post treatment mean TGV were not statistically significant (p = 0.33), while the pre-post treatment mean MTV was significantly reduced after CRT (p = 0.05). This highlights the fact that even if the tumor metabolic volume reduces its size after CRT, the persistent high metabolic activity within the tumor may be responsible for tumor recurrences. This raises the question whether dose escalation strategies are more likely to provide a therapeutic gain.

This study had several limitations including its retrospective design and a relatively small sample size of 38 patients as well as the long accrual period with consequent variations in treatment protocols according to each patient’s situation and corresponding physician’s decision, which might have affected the outcome of the patients. We used the segmentation algorithm from only one commercially available software workstation for image analysis and need to investigate other segmentation algorithms. Despite this, our study provides proof-of-concept to support the clinical value of volumetric functional assessment. Validation in a prospective and larger cohort of patients is warranted.


In the current study we demonstrated that TGV is one of the most effective independent prognostic parameters for disease outcome in LACC patients undergoing CRT. These findings suggest that combined assessment of the metabolic activity and volume of the primary tumor is more effective for prediction of prognosis in CC than a single parameter alone. These data need to be validated in a larger cohort of patients. We confirmed that the post-treatment partial tumor metabolic response is predictive of disease outcome, and this could have significant implications for the use of adjuvant as well as salvage therapies in LACC patients treated with definitive CRT.



18F-labeled fluorodeoxyglucose positron emission tomography


Complete blood count


Cervical cancer


Confidence interval


Complete metabolic response




Computer tomography


Clinical target volume


Disease-free survival


International Federation of Gynecology and Obstetrics


High-dose rate


Locally-advanced cervical cancer


Loco-regional control


Lympho-vascular space invasion


Magnetic resonance imaging


metabolic tumor volume


Overall survival


Platinum-based chemotherapy


Progressive disease


Partial metabolic response


Planning target volume


Relative risk




Standardized uptake value


Maximum standardized uptake value


Mean standardized uptake value


Total glycolytic activity within the tumor volume


Standard deviation


  1. 1.

    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893–917. doi:10.1002/ijc.25516.

  2. 2.

    Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.

  3. 3.

    Peters 3rd WA, Liu PY, Barrett 2nd RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(8):1606–13.

  4. 4.

    Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(5):1339–48.

  5. 5.

    Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(35):5802–12. doi:10.1200/JCO.2008.16.4368.

  6. 6.

    Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284):781–6. doi:10.1016/S0140-6736(01)05965-7.

  7. 7.

    Duenas-Gonzalez A, Orlando M, Zhou Y, Quinlivan M, Barraclough H. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial. Gynecologic oncology. 2012;126(3):334–40. doi:10.1016/j.ygyno.2012.06.011.

  8. 8.

    Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1678–85. doi:10.1200/JCO.2009.25.9663.

  9. 9.

    Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Science translational medicine. 2014;6(221):221ra13. doi:10.1126/scitranslmed.3007323.

  10. 10.

    Grabowska AK, Riemer AB. The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. The open virology journal. 2012;6:249–56. doi:10.2174/1874357901206010249.

  11. 11.

    Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Current cancer drug targets. 2007;7(1):79–89.

  12. 12.

    Rose PG, Java J, Whitney CW, Stehman FB, Lanciano R, Thomas GM et al. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. J Clin Oncol. 2015. doi:10.1200/JCO.2014.57.7122

  13. 13.

    Dhani N, Fyles A, Hedley D, Milosevic M. The Clinical Significance of Hypoxia in Human Cancers. Seminars in nuclear medicine. 2015;45(2):110–21. doi:10.1053/j.semnuclmed.2014.11.002.

  14. 14.

    Lim K, Chan P, Dinniwell R, Fyles A, Haider M, Cho YB, et al. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. International journal of radiation oncology, biology, physics. 2008;70(1):126–33. doi:10.1016/j.ijrobp.2007.06.033.

  15. 15.

    Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer research. 2001;61(17):6400–5.

  16. 16.

    Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, et al. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International journal of cancer Journal international du cancer. 2014;135(7):1692–9. doi:10.1002/ijc.28403.

  17. 17.

    Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer research. 2011;31(8):2589–95.

  18. 18.

    Raleigh JA, Calkins-Adams DP, Rinker LH, Ballenger CA, Weissler MC, Fowler Jr WC, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer research. 1998;58(17):3765–8.

  19. 19.

    Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer research. 2007;67(1):354–61. doi:10.1158/0008-5472.CAN-06-3388.

  20. 20.

    Hohn H, Pilch H, Gunzel S, Neukirch C, Hilmes C, Kaufmann A, et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. Journal of immunology. 1999;163(10):5715–22.

  21. 21.

    Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Frontiers in oncology. 2013;3:34. doi:10.3389/fonc.2013.00034.

  22. 22.

    Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298(19):2289–95. doi:10.1001/jama.298.19.2289.

  23. 23.

    Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738–44. doi:10.1002/cncr.22974.

  24. 24.

    Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(12):2108–13. doi:10.1200/JCO.2009.25.4151.

  25. 25.

    Yilmaz M, Adli M, Celen Z, Zincirkeser S, Dirier A. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential. Nuclear medicine communications. 2010;31(6):526–31. doi:10.1097/MNM.0b013e32833800e7.

  26. 26.

    Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003;69(3):247–50.

  27. 27.

    Bayne M, Hicks RJ, Everitt S, Fimmell N, Ball D, Reynolds J, et al. Reproducibility of “intelligent” contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. International journal of radiation oncology, biology, physics. 2010;77(4):1151–7. doi:10.1016/j.ijrobp.2009.06.032.

  28. 28.

    Vali FS, Nagda S, Hall W, Sinacore J, Gao M, Lee SH, et al. Comparison of standardized uptake value-based positron emission tomography and computed tomography target volumes in esophageal cancer patients undergoing radiotherapy. International journal of radiation oncology, biology, physics. 2010;78(4):1057–63. doi:10.1016/j.ijrobp.2009.09.022.

  29. 29.

    Zhang Y, Hu J, Lu HJ, Li JP, Wang N, Li WW, et al. Determination of an optimal standardized uptake value of fluorodeoxyglucose for positron emission tomography imaging to assess pathological volumes of cervical cancer: a prospective study. PloS one. 2013;8(11), e75159. doi:10.1371/journal.pone.0075159.

  30. 30.

    Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18 F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53(5):709–15. doi:10.2967/jnumed.111.099531.

  31. 31.

    Lim K, Small Jr W, Portelance L, Creutzberg C, Jurgenliemk-Schulz IM, Mundt A, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. International journal of radiation oncology, biology, physics. 2011;79(2):348–55. doi:10.1016/j.ijrobp.2009.10.075.

  32. 32.

    Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. International journal of radiation oncology, biology, physics. 2005;63(5):1604–12. doi:10.1016/j.ijrobp.2005.05.062.

  33. 33.

    Kaplan ES MP. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. doi:10.2307/2281868.

  34. 34.

    Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal immunology. 2008;1(5):412–20. doi:10.1038/mi.2008.33.

  35. 35.

    Cox DR. Regression models and life tables. J Roy Stat Soc. 1972;34:187–220.

  36. 36.

    Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR American journal of roentgenology. 2013;200(3):635–40. doi:10.2214/AJR.12.9138.

  37. 37.

    Chan WK, Mak HK, Huang B, Yeung DW, Kwong DL, Khong PL. Nasopharyngeal carcinoma: relationship between 18 F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification. Nuclear medicine communications. 2010;31(3):206–10. doi:10.1097/MNM.0b013e328333e3ef.

  38. 38.

    Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;89(3):278–86. doi:10.1016/j.radonc.2008.06.014.

  39. 39.

    Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. International journal of radiation oncology, biology, physics. 2013;85(1):116–22. doi:10.1016/j.ijrobp.2012.02.056.

  40. 40.

    Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecologic oncology. 2000;78(2):187–93. doi:10.1006/gyno.2000.5860.

  41. 41.

    Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecologic oncology. 2009;112(1):104–9. doi:10.1016/j.ygyno.2008.08.028.

Download references


The authors are grateful to Ms. Julia Rengier-Styles for her help in preparing the manuscript.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

As the study was a retrospective data extraction from our hospital records without direct treatment intervention the informed consent for study participation was not a requirement.

Author information

Correspondence to Mahmut Ozsahin.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

FGH: conception, design, acquisition of data, analysis and interpretation of data. Drafted the manuscript. Gave final approval to the version to be published. TB: acquisition of data and interpretation. JOP: conception, design, analysis and interpretation of data. JB: accountable for all aspects of the work. MO: accountable for all aspects of the work, gave final approval of the version to be published. All authors read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Herrera, F.G., Breuneval, T., Prior, J.O. et al. [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol 11, 43 (2016) doi:10.1186/s13014-016-0614-x

Download citation


  • [18F]FDG-PET/CT
  • Cervical cancer
  • Chemo-radiotherapy
  • Tumor glycolytic volume
  • Standard uptake value


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.